Quick Dispatch:
Your surpass 6 tirzepatide Frias_Tirzepatide: Overview of SURPASS Trials in Patients With Type 2 Diabetes orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your surpass 6 tirzepatide Frias_Tirzepatide: Overview of SURPASS Trials in Patients With Type 2 Diabetes ships.
Need Help?
Questions about surpass 6 tirzepatide Frias_Tirzepatide: Overview of SURPASS Trials in Patients With Type 2 Diabetes, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for surpass 6 tirzepatide Frias_Tirzepatide: Overview of SURPASS Trials in Patients With Type 2 Diabetes in your area.
In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%
26.19
Diabetes Distilled: “Twincretin” tirzepatide significantly SURPASSes comparator effects on glucose, weight and quality of life
28.93
Frontiers
28.73
Should Diabetes Management be More Adipose-Centric?
29.94
Did Tirzepatide Steal the Show at EASD?
25.09
Tirzepatide Improved Health-Related Quality of Life Compared with Insulin Lispro in Basal Insulin-Treated Adults with Type 2 Diabetes and Inadequate Glycaemic Control: A Randomised Controlled Phase 3b Trial (SURPASS-6)
21.96
01774-X/asset/3608bfb3-6329-4132-95b7-cc3434437493/main.assets/gr2_lrg.jpg)
Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial
23.62
